Transplantation in chronic lymphocytic leukemia: timing and expectations.
Stem cell transplantation in chronic lymphocytic leukemia (CLL) is an evolving field. Younger patients with high-risk disease might derive the greatest benefit from this approach and the availability of reduced-intensity conditioning regimens has made allogeneic stem cell transplantation more relevant to patients with CLL. Patient selection, timing of transplantation, and method of conditioning, stem cell delivery and immunosuppression appear to influence outcomes. We collect and review the available data to assist clinical decision-making in this field.
Institute of Cancer, Bart's and the London School of Medicine, Charterhouse Square, London, EC1M 6BQ, UK.
Simon
S
Hallam
John G
JG
Gribben
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D018579:Patient Selection; D013234:Stem Cells / Q000166:cytology; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
D007166:Immunosuppressive Agents